The good news is that the team at UBS don’t believe that Vyvgart will have an overly large impact on CSL’s revenue. It sees the worst-case scenario as a ~3% revenue hit. Though, even then, the broker feels that is unlikely.As a result, it may be unnecessary to worry too much about this news. And with UBS retaining its buy rating and $340.00 price target, it could prove to be an opportune time to pick up CSL shares while they are cheap.
UBS - CSL no need to worry about Argenx
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$280.92 |
Change
-1.080(0.38%) |
Mkt cap ! $135.7B | |||
| Open | High | Low | Value | Volume |
| $279.09 | $281.93 | $279.04 | $158.3M | 564.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 250 | $280.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $281.00 | 199 | 2 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$280.90 |
Change
-1.080 ( 0.70 %) |
||||
| Open | High | Low | Volume | ||
| $279.61 | $282.55 | $279.06 | 59791 | ||
| Last updated 15.59pm 24/05/2024 ? | |||||
| CSL (ASX) Chart |